Jacob Bell

1 month ago | pharmavoice.com | Jacob Bell |Jacob Bell

This audio is auto-generated. Please let us know if you have feedback. Eli Lilly is wagering up to $1 billion on a private biotechnology company developing new, non-opioid pain drugs that have already caught the attention of other large pharmaceutical firms. Per an announcement Tuesday, Lilly plans to acquire SiteOne Therapeutics in an all-cash deal. The companies aren’t disclosing how much money is being exchanged upfront or when they expect the transaction to close.